

SERUM AMYLIN IN PATIENTS
WITH GESTATIONAL
DIABETES

Thesis submitted for partial fulfillment of the Master
Degree in Internal Medicine

Presented by

IMAN FATHY EL-SAMMAN

616.462

MB. BC4

54659

E. F Under the supervision of

PROF. DR. MOHAMED FAHMY ABD EL-AZIZ

Professor of Internal Medicine and Endocrinology

Faculty of Medicine-Ain Shams University

DR. RAEF MALAAK BOTROS

Lecturer of Internal Medicine

Faculty of Medicine-Ain Shams University

DR. HALA MOHAMED MAHFOUZ

Lecturer of Internal Medicine

Faculty of Medicine-Ain Shams University

FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY
1997





بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ

لَنَا إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

(سورة البقرة)

(الاية ٣٢)

ACKNOWLEDGMENT

*I wish to express my deepest gratitude and appreciation to Professor Dr., **Mohamed Fahmy Abd El-Aziz**, Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, to whom I am greatly indebted for his patience, supervision and valuable suggestions with his advice which allowed me to go through lots of difficulties during this work.*

*I wish also to express my gratitude and thanks to Dr., **Raef Malaak Botros**, Lecturer of Internal Medicine, Ain Shams University, for his sincere support and generous ideas during the course of this work.*

*I am also grateful to Dr., **Hala Mohamed Mahfouz**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her support.*

*I also own a lot for Professor Dr., **Gehan Kamal Hassan Ali**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University for her expert practical assistance in our laboratory work.*

*I am very grateful for Dr., **Mohamed Reda Abd El-Aal**, Fellow of Obstetrics and Gynecology, Director of Gestational Diabetics Outpatient Clinic, Faculty of Medicine, Ain Shams University, for his sincere help in clinical material.*

Eman El-Samman
1997

LIST OF CONTENTS

	<i>Page #</i>
<i>Introduction and Aim of the Work</i>	<i>1-2</i>
<i>Chapter 1: Amylin</i>	<i>(3-40)</i>
-Structure, chemical and biological aspects of amylin	3-8
-Amylin's correlations, factors regulating its secretion, actions	8-25
-Fibrillogenesis, amyloidogenicity and cytotoxicity of amylin	26-34
-Amylin and pathogenesis of non-insulin dependent diabetes mellitus	35-37
-Amylin in insulin-dependent diabetes mellitus	38-39
-Therapeutic applications of amylin analogues and blockers	39-40
<i>Chapter 2: Diabetes Mellitus</i>	<i>(41-64)</i>
-Introduction, epidemiology and classification	41-45
-Etiology of insulin dependent diabetes mellitus (IDDM)	46-52
-Role of cell adhesion molecules in pathogenesis of (IDDM)	53-56
-Etiology of non-insulin dependent diabetes mellitus (NIDDM)	56-58
-Pathogenesis of NIDDM	58-64
<i>Chapter 3: Gestational Diabetes Mellitus (GDM)</i>	<i>(65-100)</i>
-Introduction, risk factors, classification of diabetes in pregnancy	65-68

-Pathogenesis of gestational diabetes	68-75
-Metabolic changes in normal pregnancy and pregnancy complicated by GDM	75-79
-Complications of GDM	80-92
-Screening and diagnostic tests for carbohydrate intolerance during pregnancy	92-96
-Management of GDM	96-100
<i>Chapter 4: Materials and Methods</i>	(101-122)
<i>Chapter 5: Results</i>	(123-140)
<i>Chapter 6: Discussion and Conclusion</i>	(141-151)
<i>Summary</i>	(152-154)
<i>References</i>	(155-183)
<i>Appendix</i>	
<i>Arabic Summary</i>	

LIST OF TABLES

	<i>Page #</i>
<i>Table 2.1: Classification of Diabetes Mellitus</i>	43
<i>Table 2.2: Risk of developing IDDM in an individual with a first degree relative with IDDM</i>	47
<i>Table 3.1: Modified White Classification of pregnant diabetic women</i>	68
<i>Table 4.1: Carpenter-Coustan modification of NDGG criteria</i>	107
<i>Table 5.1: Clinical parameters of Groups I and II</i>	128
<i>Table 5.2: Clinical parameters of Groups I and III</i>	128
<i>Table 5.3: Clinical parameters of Groups II and III</i>	129
<i>Table 5.4: Clinical parameters of subgroups IIIa and IIIb</i>	129
<i>Table 5.5: OGTT in Group II</i>	130
<i>Table 5.6: OGTT in Groups II and III</i>	130
<i>Table 5.7: OGTT in subgroups IIIa and IIIb</i>	131
<i>Table 5.8: C-peptide, glycosylated hemoglobin, and amylin levels in Groups I and II</i>	133
<i>Table 5.9: C-peptide, glycosylated hemoglobin, and amylin levels in Groups I and III</i>	133
<i>Table 5.10: C-peptide, glycosylated hemoglobin, and amylin levels in Groups II and III</i>	134
<i>Table 5.11: C-peptide, glycosylated hemoglobin, and amylin levels in Subgroups IIIa and IIIb</i>	134
<i>Table 5.12: Correlations of C-peptide, glycosylated hemoglobin and amylin in all groups</i>	137

LIST OF FIGURES

	<i>Page #</i>
<i>Fig 2.1: The diabetic prodrome</i>	49
<i>Fig 3.1: Newborn weight correlation to gestational age</i>	87
<i>Fig 5.1: OGTT in all Groups</i>	131
<i>Fig 5.2: OGTT in Groups I, II, IIIa, IIIb</i>	132
<i>Fig 5.3: OGTT in all Groups and Subgroups</i>	132
<i>Fig 5.4: Bar chart for fasting glucose level in all groups and subgroups</i>	135
<i>Fig 5.5: Bar chart for Glyco Hb% in all groups and subgroups</i>	135
<i>Fig 5.6: Bar chart for C-peptide in all groups and subgroups</i>	136
<i>Fig 5.7: Bar chart for amylin in all groups and subgroups</i>	136
<i>Fig 5.8: Scattered diagram for correlation between amylin and fasting blood glucose in Group III</i>	138
<i>Fig 5.9: Scattered diagram for correlation between amylin and glycosylated hemoglobin in Group III</i>	139
<i>Fig 5.10: Scattered diagram for correlation between amylin and C-peptide in Group III</i>	140

*Introduction and
Aim of the Work*

